Growth Equity Opportunities Fund IV, LLC 13D and 13G filings for AVEO Pharmaceuticals, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2022-11-01 5:01 pm Sale |
2022-10-20 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 0 0.000% |
-5,424,009 (Position Closed) |
Filing |
| 2020-06-24 5:03 pm Purchase |
2020-06-19 | 13D | AVEO Pharmaceuticals, Inc. AVEO |
Growth Equity Opportunities Fund IV, LLC | 5,424,009 20.800% |
1,428,570 (+35.76%) |
Filing |